Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of Cefepime-Enmetazobactam in Pediatric Patients With cUTI
NCT05826990Phase 2Recruiting
- Sponsor
- Orchid Pharma
- Start
- Sep 2023
- Primary completion
- May 2029
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, open-label, single-arm trial of cefepime + enmetazobactam in complicated urinary tract infection (cUTI) and acute pyelonephritis, sponsored by Orchid Pharma. Primary endpoints: Maximum Observed Plasma Concentration at Day 2, Time to Maximum Plasma Concentration at Day 2 and 6 more. Started Sep 2023; status: recruiting.
02
Drugs
cefepime + enmetazobactam
03
Conditions
complicated urinary tract infection (cUTI)acute pyelonephritis
Beyond the preview
Go deeper on NCT05826990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05826990.